{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:53:51Z","timestamp":1790686431032,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["13\/RC\/2073_2"],"award-info":[{"award-number":["13\/RC\/2073_2"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40259-022-00562-6","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T05:02:55Z","timestamp":1666674175000},"page":"687-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-8344","authenticated-orcid":false,"given":"David J.","family":"Brayden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"issue":"4","key":"562_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","volume":"19","author":"DJ Drucker","year":"2020","unstructured":"Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277\u201389. https:\/\/doi.org\/10.1038\/s41573-019-0053-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"562_CR2","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.apsb.2021.04.001","volume":"11","author":"Q Zhu","year":"2021","unstructured":"Zhu Q, Chen Z, Paul PK, Lu Y, Wu W, Qi J. Oral delivery of proteins and peptides: challenges, status quo and future perspectives. Acta Pharm Sin B. 2021;11(8):2416\u201348. https:\/\/doi.org\/10.1016\/j.apsb.2021.04.001.","journal-title":"Acta Pharm Sin B."},{"key":"562_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejpb.2020.08.017","volume":"155","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Thanou M, Vllasaliu D. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease. Eur J Pharm Biopharm. 2020;155:128\u201338. https:\/\/doi.org\/10.1016\/j.ejpb.2020.08.017.","journal-title":"Eur J Pharm Biopharm"},{"key":"562_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2020.05.007","volume":"157","author":"DJ Brayden","year":"2020","unstructured":"Brayden DJ, Hill TA, Fairlie DP, Maher S, Mrsny RJ. Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches. Adv Drug Deliv Rev. 2020;157:2\u201336. https:\/\/doi.org\/10.1016\/j.addr.2020.05.007.","journal-title":"Adv Drug Deliv Rev"},{"issue":"467","key":"562_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"ST Buckley","year":"2018","unstructured":"Buckley ST, B\u00e6kdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-R\u00f8nne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467): eaar7047. https:\/\/doi.org\/10.1126\/scitranslmed.aar7047.","journal-title":"Sci Transl Med."},{"issue":"7","key":"562_CR6","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1210\/jc.2012-1179","volume":"97","author":"S Tuvia","year":"2012","unstructured":"Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab. 2012;97(7):2362\u20139. https:\/\/doi.org\/10.1210\/jc.2012-1179.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"562_CR7","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/pharmaceutics13071006","volume":"13","author":"RJ Mrsny","year":"2021","unstructured":"Mrsny RJ, Mahmood TA. Re-assessing PK\/PD issues for oral protein and peptide delivery. Pharmaceutics. 2021;13(7):1006. https:\/\/doi.org\/10.3390\/pharmaceutics13071006.","journal-title":"Pharmaceutics"},{"key":"562_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.addr.2016.01.010","volume":"101","author":"E Moroz","year":"2016","unstructured":"Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv Drug Deliv Rev. 2016;101:108\u201321. https:\/\/doi.org\/10.1016\/j.addr.2016.01.010.","journal-title":"Adv Drug Deliv Rev"},{"key":"562_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2018.10.009","volume":"136\u2013137","author":"A Bak","year":"2018","unstructured":"Bak A, Ashford M, Brayden DJ. Local delivery of macromolecules to treat diseases associated with the colon. Adv Drug Deliv Rev. 2018;136\u2013137:2\u201327. https:\/\/doi.org\/10.1016\/j.addr.2018.10.009.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"562_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/apt.12604","volume":"39","author":"P Layer","year":"2014","unstructured":"Layer P, Stanghellini V. Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014;39(4):371\u201384. https:\/\/doi.org\/10.1111\/apt.12604.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"562_CR11","doi-asserted-by":"publisher","first-page":"8384","DOI":"10.1021\/acs.jmedchem.1c00380","volume":"64","author":"N Braga Emidio","year":"2021","unstructured":"Braga Emidio N, Tran HNT, Andersson A, Dawson PE, Albericio F, Vetter I, et al. Improving the gastrointestinal stability of linaclotide. J Med Chem. 2021;64(12):8384\u201390. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00380.","journal-title":"J Med Chem"},{"issue":"2","key":"562_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1185\/03007995.2012.754743","volume":"29","author":"JM Johnston","year":"2013","unstructured":"Johnston JM, Shiff SJ, Quigley EM. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Curr Med Res Opin. 2013;29(2):149\u201360. https:\/\/doi.org\/10.1185\/03007995.2012.754743.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"562_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1136\/gutjnl-2018-316029","volume":"67","author":"SA Waldman","year":"2018","unstructured":"Waldman SA, Camilleri M. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut. 2018;67(8):1543\u201352. https:\/\/doi.org\/10.1136\/gutjnl-2018-316029.","journal-title":"Gut"},{"key":"562_CR14","doi-asserted-by":"publisher","first-page":"175628481877794","DOI":"10.1177\/1756284818777945","volume":"11","author":"SSC Rao","year":"2018","unstructured":"Rao SSC. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Ther Adv Gastroenterol. 2018;11:1756284818777945. https:\/\/doi.org\/10.1177\/1756284818777945.","journal-title":"Ther Adv Gastroenterol"},{"issue":"10\u201312","key":"562_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1080\/15384047.2021.1967036","volume":"22","author":"DS Weinberg","year":"2021","unstructured":"Weinberg DS, Foster NR, Della\u2019Zanna G, McMurray RP, Kraft WK, Pallotto A, et al. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biol Ther. 2021;22(10\u201312):544\u201353. https:\/\/doi.org\/10.1080\/15384047.2021.1967036.","journal-title":"Cancer Biol Ther"},{"key":"562_CR16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","volume":"11","author":"M Rosario","year":"2017","unstructured":"Rosario M, French J, Dirk NL, Sankoh S, Parikh A, Yang H, et al. Exposure\u2013efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn\u2019s disease. J Crohns Colitis. 2017;11:921\u20139.","journal-title":"J Crohns Colitis"},{"key":"562_CR17","unstructured":"Bhandari A, Patel DV, Zemede G, Mattheakis LC, Liu D. \u03b14\u03b27 peptide monomer and dimer antagonists. USP 9,809,623."},{"issue":"6","key":"562_CR18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1053\/j.gastro.2021.08.045","volume":"161","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Mattheakis LC, Modi NB, Pugatch D, Bressler B, Lee S, et al. PTG-100, an Oral \u03b14\u03b27 antagonist peptide: preclinical development and Phase I and 2a Studies in ulcerative colitis. Gastroenterology. 2021;161(6):1853-1864.e10. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.045.","journal-title":"Gastroenterology"},{"issue":"10","key":"562_CR19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/13543784.2021.1974396","volume":"30","author":"V Solitano","year":"2021","unstructured":"Solitano V, Parigi TL, Ragaini E, Danese S. Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents. Expert Opin Investig Drugs. 2021;30(10):1037\u201346. https:\/\/doi.org\/10.1080\/13543784.2021.1974396.","journal-title":"Expert Opin Investig Drugs"},{"key":"562_CR20","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/S0016-5085(19)36988-4","volume":"156","author":"L Mattheakis","year":"2019","unstructured":"Mattheakis L, Tang T, Venkataraman S, Rao N, Li Wang L, Zhao L, et al. The oral \u03b14\u03b27 integrin specific antagonist PN-10943 is more effective than PTG-100 in multiple preclinical studies. Gastroenterology. 2019;156:S80\u20131.","journal-title":"Gastroenterology"},{"issue":"11","key":"562_CR21","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/cpdd.946","volume":"10","author":"NB Modi","year":"2021","unstructured":"Modi NB, Cheng X, Mattheakis L, Hwang CC, Nawabi R, Liu D, et al. Single- and multiple-dose pharmacokinetics and pharmacodynamics of PN-943, a gastrointestinal-restricted oral peptide antagonist of \u03b14\u03b27, in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10(11):1263\u201378. https:\/\/doi.org\/10.1002\/cpdd.946.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"562_CR22","unstructured":"https:\/\/www.protagonist-inc.com\/investors-media\/press-releases\/news-details\/2022\/Protagonist-Therapeutics-Announces-Topline-Data-from-Phase-2-IDEAL-Study-of-PN-943-in-Ulcerative-Colitis\/default.aspx. Accessed 10 Oct 2022."},{"issue":"10","key":"562_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1136\/gut.2005.083634","volume":"55","author":"C Maaser","year":"2006","unstructured":"Maaser C, Kannengiesser K, Specht C, L\u00fcgering A, Brzoska T, Luger TA, et al. Crucial role of the melanocortin receptor MC1R in experimental colitis. Gut. 2006;55(10):1415\u201322.","journal-title":"Gut"},{"key":"562_CR24","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3389\/fphar.2018.01535","volume":"9","author":"C Spana","year":"2018","unstructured":"Spana C, Taylor AW, Yee DG, Makhlina M, Yang W, Dodd J. Probing the role of melanocortin type 1 receptor agonists in diverse immunological diseases. Front Pharmacol. 2018;9:1535.","journal-title":"Front Pharmacol"},{"key":"562_CR25","unstructured":"Dhingra P, Obr A, Spana C, Dodd JH, Kayne PS. Cellular and molecular impact of the Melanocortin receptor agonist PL8177 in dextran sulfate sodium (DSS)-induced colitis in rats. In: Crohns and Colitis Congress (2022). https:\/\/palatin.com\/wp-content\/uploads\/2022\/01\/PAL-G21PL8.2008-CCC-2021-Dhingra-DSS-Rat-Genomic-Poster-0119-2.pdf. Accessed 10 Oct 2022."},{"issue":"6337","key":"562_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1126\/science.aal353","volume":"356","author":"WKE Ip","year":"2017","unstructured":"Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356(6337):513\u20139. https:\/\/doi.org\/10.1126\/science.aal353.","journal-title":"Science"},{"issue":"1","key":"562_CR27","doi-asserted-by":"publisher","first-page":"1710429","DOI":"10.1080\/21688370.2019.1710429","volume":"8","author":"A Taverner","year":"2020","unstructured":"Taverner A, MacKay J, Laurent F, Hunter T, Liu K, Mangat K, et al. Cholix protein domain I functions as a carrier element for efficient apical to basal epithelial transcytosis. Tissue Barriers. 2020;8(1):1710429. https:\/\/doi.org\/10.1080\/21688370.2019.1710429.","journal-title":"Tissue Barriers."},{"issue":"8","key":"562_CR28","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1097\/MIB.0000000000000468","volume":"21","author":"LM Keubler","year":"2015","unstructured":"Keubler LM, Buettner M, H\u00e4ger C, Bleich A. A multihit model: colitis lessons from the interleukin-10-deficient mouse. Inflamm Bowel Dis. 2015;21(8):1967\u201375. https:\/\/doi.org\/10.1097\/MIB.0000000000000468.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"562_CR29","doi-asserted-by":"publisher","first-page":"CD005109","DOI":"10.1002\/14651858.CD005109","volume":"2010","author":"FE Buruiana","year":"2010","unstructured":"Buruiana FE, Sol\u00e0 I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2010;2010(11):CD005109. https:\/\/doi.org\/10.1002\/14651858.CD005109.","journal-title":"Cochrane Database Syst Rev"},{"key":"562_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2022.2039003","author":"K Liu","year":"2022","unstructured":"Liu K, Hunter T, Taverner A, Yin K, MacKay J, Colebrook K, et al. GRP75 as a functional element of cholix transcytosis. Tissue Barriers. 2022. https:\/\/doi.org\/10.1080\/21688370.2022.2039003.","journal-title":"Tissue Barriers."},{"issue":"11","key":"562_CR31","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.4049\/jimmunol.2000848","volume":"205","author":"NC Fay","year":"2020","unstructured":"Fay NC, Muthusamy BP, Nyugen LP, Desai RC, Taverner A, MacKay J, et al. A novel fusion of IL-10 engineered to traffic across intestinal epithelium to treat colitis. J Immunol. 2020;205(11):3191\u2013204. https:\/\/doi.org\/10.4049\/jimmunol.2000848.","journal-title":"J Immunol"},{"key":"562_CR32","unstructured":"https:\/\/www.appliedmt.com\/pipeline\/amt-101\/. Accessed 10 Oct 2022."},{"key":"562_CR33","unstructured":"https:\/\/ir.appliedmt.com\/news-releases\/news-release-details\/applied-molecular-transport-announces-top-line-phase-2-results. Accessed 10 Oct 2022."},{"issue":"3","key":"562_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.imbio.2016.11.001","volume":"222","author":"Y Ilan","year":"2017","unstructured":"Ilan Y, Gingis-Velitski S, Ben Ya\u2019aco A, Shabbat Y, Zolotarov L, Almon E, et al. A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis. Immunobiology. 2017;222(3):544\u201351. https:\/\/doi.org\/10.1016\/j.imbio.2016.11.001.","journal-title":"Immunobiology"},{"issue":"39","key":"562_CR35","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.3748\/wjg.v22.i39.8760","volume":"22","author":"Y Ilan","year":"2016","unstructured":"Ilan Y, Ben Ya\u2019acov A, Shabbat Y, Gingis-Velitski S, Almon E, Shaaltiel Y. Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis. World J Gastroenterol. 2016;22(39):8760\u20139. https:\/\/doi.org\/10.3748\/wjg.v22.i39.8760.","journal-title":"World J Gastroenterol"},{"key":"562_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jim.2017.03.023","volume":"446","author":"E Almon","year":"2017","unstructured":"Almon E, Khoury T, Drori A, Gingis-Velitski S, Alon S, Chertkoff R, et al. An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. J Immunol Methods. 2017;446:21\u20139. https:\/\/doi.org\/10.1016\/j.jim.2017.03.023.","journal-title":"J Immunol Methods"},{"issue":"2","key":"562_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/MCG.0000000000001314","volume":"55","author":"E Almon","year":"2021","unstructured":"Almon E, Shaaltiel Y, Sbeit W, Fich A, Schwartz D, Waterman M, et al. Novel orally administered recombinant anti-TNF alpha fusion protein for the treatment of ulcerative colitis: results from a phase IIa clinical trial. J Clin Gastroenterol. 2021;55(2):134\u201340. https:\/\/doi.org\/10.1097\/MCG.0000000000001314.","journal-title":"J Clin Gastroenterol"},{"key":"562_CR38","unstructured":"https:\/\/protalix.com\/pipeline\/. Accessed 5 July 2022."},{"issue":"11","key":"562_CR39","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1097\/MIB.0b013e3182a11958","volume":"19","author":"KC Bhol","year":"2013","unstructured":"Bhol KC, Tracey DE, Lemos BR, Lyng GD, Erlich EC, Keane DM, et al. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(11):2273\u201381. https:\/\/doi.org\/10.1097\/MIB.0b013e3182a11958.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"562_CR40","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/ecco-jcc\/jjw036","volume":"10","author":"MS Harris","year":"2016","unstructured":"Harris MS, Hartman D, Lemos BR, Erlich EC, Spence S, Kennedy S, et al. AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. J Crohns Colitis. 2016;10(6):631\u201340. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw036.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"562_CR41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/ecco-jcc\/jjw026","volume":"10","author":"DS Hartman","year":"2016","unstructured":"Hartman DS, Tracey DE, Lemos BR, Erlich EC, Burton RE, Keane DM, et al. Effects of AVX-470, an oral, locally acting anti-tumour necrosis factor antibody, on tissue bomarkers in patients with active ulcerative colitis. J Crohns Colitis. 2016;10(6):641\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw026.","journal-title":"J Crohns Colitis"},{"key":"562_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.675194","volume":"9","author":"W Zhang","year":"2021","unstructured":"Zhang W, Michalowski CB, Beloqui A. Oral delivery of biologics in inflammatory bowel disease treatment. Front Bioeng Biotechnol. 2021;9: 675194. https:\/\/doi.org\/10.3389\/fbioe.2021.675194.","journal-title":"Front Bioeng Biotechnol."},{"issue":"1","key":"562_CR43","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1038\/s41598-018-23277-7","volume":"8","author":"JS Crowe","year":"2018","unstructured":"Crowe JS, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Clare S, et al. Preclinical development of a novel, orally administered anti-tumour necrosis factor domain antibody for the treatment of inflammatory bowel disease. Sci Rep. 2018;8(1):4941. https:\/\/doi.org\/10.1038\/s41598-018-23277-7.","journal-title":"Sci Rep"},{"issue":"3","key":"562_CR44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/03639045.2018.1542708","volume":"45","author":"JS Crowe","year":"2019","unstructured":"Crowe JS, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Ray KP, et al. Oral delivery of the anti-tumor necrosis factor \u03b1 domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys. Drug Dev Ind Pharm. 2019;45(3):387\u201394. https:\/\/doi.org\/10.1080\/03639045.2018.1542708.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"562_CR45","doi-asserted-by":"publisher","first-page":"14042","DOI":"10.1038\/s41598-019-50545-x","volume":"9","author":"S Nurbhai","year":"2019","unstructured":"Nurbhai S, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Ray KP, et al. Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations and reduces markers of inflammation in ulcerative colitis patients. Sci Rep. 2019;9(1):14042. https:\/\/doi.org\/10.1038\/s41598-019-50545-x.","journal-title":"Sci Rep"},{"issue":"1","key":"562_CR46","doi-asserted-by":"publisher","first-page":"19422","DOI":"10.1038\/s41598-021-97236-0","volume":"11","author":"KJ Roberts","year":"2021","unstructured":"Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, et al. Preclinical development of a bispecific TNF\u03b1\/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep. 2021;11(1):19422. https:\/\/doi.org\/10.1038\/s41598-021-97236-0.","journal-title":"Sci Rep"},{"issue":"5","key":"562_CR47","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1053\/j.gastro.2012.07.019","volume":"143","author":"K Forster","year":"2012","unstructured":"Forster K, Goethel A, Chan CW, Zanello G, Streutker C, Croitoru K. An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology. 2012;143(5):1298\u2013307. https:\/\/doi.org\/10.1053\/j.gastro.2012.07.019.","journal-title":"Gastroenterology"},{"issue":"2","key":"562_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otz009","volume":"1","author":"EK Boden","year":"2019","unstructured":"Boden EK, Canavan JB, Moran CJ, McCann K, Dunn WA, Farraye FA, et al. Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis. J Crohns Colitis 360. 2019;1(2): otz009. https:\/\/doi.org\/10.1093\/crocol\/otz009.","journal-title":"J Crohns Colitis 360."},{"issue":"1","key":"562_CR49","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12951-021-01090-1","volume":"19","author":"P Eder","year":"2021","unstructured":"Eder P, Zieli\u0144ska A, Karczewski J, Dobrowolska A, S\u0142omski R, Souto EB. How could nanobiotechnology improve treatment outcomes of anti-TNF-\u03b1 therapy in inflammatory bowel disease? Current knowledge, future directions. J Nanobiotechnol. 2021;19(1):346. https:\/\/doi.org\/10.1186\/s12951-021-01090-1.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"562_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41587-021-01024-0","volume":"40","author":"A Abramson","year":"2022","unstructured":"Abramson A, Frederiksen MR, Vegge A, Jensen B, Poulsen M, Mouridsen B, et al. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors. Nat Biotechnol. 2022;40(1):103\u20139. https:\/\/doi.org\/10.1038\/s41587-021-01024-0.","journal-title":"Nat Biotechnol"},{"key":"562_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-981-13-7709-9_14","volume":"1148","author":"GA Ketwaroo","year":"2019","unstructured":"Ketwaroo GA, Graham DY. Rational use of pancreatic enzymes for pancreatic insufficiency and pancreatic pain. Adv Exp Med Biol. 2019;1148:323\u201343. https:\/\/doi.org\/10.1007\/978-981-13-7709-9_14.","journal-title":"Adv Exp Med Biol"},{"key":"562_CR52","doi-asserted-by":"publisher","first-page":"569215","DOI":"10.3389\/fmed.2020.569215","volume":"7","author":"K Pierzynowska","year":"2020","unstructured":"Pierzynowska K, Deshpande A, Mosiichuk N, Terkeltaub R, Szczurek P, Salido E, et al. Oral treatment with an engineered uricase, ALLN-346, reduces hyperuricemia, and uricosuria in urate oxidase-deficient mice. Front Med (Lausanne). 2020;7:569215. https:\/\/doi.org\/10.3389\/fmed.2020.569215.","journal-title":"Front Med (Lausanne)."},{"issue":"Suppl. 1","key":"562_CR53","first-page":"906","volume":"81","author":"D Clark","year":"2022","unstructured":"Clark D, Grujic D, Tosone C, Dahl N, Terkeltaub R. Phase I trials of novel oral enzyme therapy (ALLN-346) for hyperuricemia and gout: safety, pharmacodynamics, and lack of systemic absorption of single and multiple ascending doses in healthy volunteers. EULAR J. 2022;81(Suppl. 1):906\u20137 (POS1156).","journal-title":"EULAR J."},{"issue":"Suppl. 1","key":"562_CR54","first-page":"907","volume":"81","author":"R Terkeltaub","year":"2022","unstructured":"Terkeltaub R, Clark D, Tosone C, Kandinov B, Zhang P, Dahl N, et al. Safety and efficacy of ALLN-346 oral enzyme therapy om patients with hyperuricemia and chronic kidney disease (CKD): results of the phase IIA study 201. EULAR J. 2022;81(Suppl. 1):907 (POS1157).","journal-title":"EULAR J."},{"key":"562_CR55","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1053\/j.gastro.2006.09.016","volume":"131","author":"M Boirivant","year":"2006","unstructured":"Boirivant M, Pallone F, Di Giacinto C, Fina D, Monteleone I, Marinaro M, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF \u03b2 1-mediated suppression of colitis. Gastroenterology. 2006;131:1786\u201398.","journal-title":"Gastroenterology"},{"key":"562_CR56","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","volume":"372","author":"G Monteleone","year":"2015","unstructured":"Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease. N Engl J Med. 2015;372:1104\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1407250.","journal-title":"N Engl J Med"},{"issue":"5","key":"562_CR57","doi-asserted-by":"publisher","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","volume":"115","author":"BE Sands","year":"2020","unstructured":"Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Colombel JF, et al. Mongersen (GED-0301) for active Crohn\u2019s disease: results of a Phase III study. Am J Gastroenterol. 2020;115(5):738\u201345. https:\/\/doi.org\/10.14309\/ajg.0000000000000493.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"562_CR58","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40259-021-00482-x","volume":"35","author":"I Marafini","year":"2021","unstructured":"Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, et al. A pharmacological batch of mongersen that downregulates Smad7 is effective as induction therapy in active Crohn\u2019s disease: a phase II, open-Label study. BioDrugs. 2021;35(3):325\u201336. https:\/\/doi.org\/10.1007\/s40259-021-00482-x.","journal-title":"BioDrugs"},{"issue":"4","key":"562_CR59","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/nat.2021.0089","volume":"32","author":"L Arrico","year":"2022","unstructured":"Arrico L, Stolfi C, Marafini I, Monteleone G, Demartis S, Bellinvia S, Viti F, McNulty M, Cabani I, Falezza A, Di Bari L. Inhomogeneous diastereomeric composition of mongersen antisense phosphorothioate oligonucleotide preparations and related pharmacological activity impairment. Nucleic Acid Ther. 2022;32(4):312\u201320. https:\/\/doi.org\/10.1089\/nat.2021.0089.","journal-title":"Nucleic Acid Ther"},{"issue":"5","key":"562_CR60","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40291-022-00606-1","volume":"26","author":"G Monteleone","year":"2022","unstructured":"Monteleone G, Stolfi C, Marafini I, Atreya R, Neurath MF. Smad7 antisense oligonucleotide-based therapy in Crohn\u2019s disease: is it time to re-evaluate? Mol Diagn Ther. 2022;26(5):477\u201381. https:\/\/doi.org\/10.1007\/s40291-022-00606-1.","journal-title":"Mol Diagn Ther"},{"issue":"suppl 2","key":"562_CR61","doi-asserted-by":"publisher","first-page":"S669","DOI":"10.1093\/ecco-jcc\/jjy059","volume":"12","author":"W Reinisch","year":"2018","unstructured":"Reinisch W, Hung K, Hassan-Zahraee M, Cataldi F. Targeting endothelial ligands: ICAM-1\/alicaforsen, MAdCAM-1. J Crohns Colitis. 2018;12(suppl 2):S669\u201377. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy059.","journal-title":"J Crohns Colitis"},{"key":"562_CR62","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.14309\/01.ajg.0000776672.02201.55","volume":"116","author":"F Feagan","year":"2021","unstructured":"Feagan F, Lindsay J, Rogler R, Moran G, Varawalla N. Alicaforsen enema in chronic pouchitis: results of a phase III randomized, double-blind, placebo-controlled Trial. Am J Gastroenterol. 2021;116:S365. https:\/\/doi.org\/10.14309\/01.ajg.0000776672.02201.55.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"562_CR63","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/jps.20051","volume":"93","author":"AA Raoof","year":"2004","unstructured":"Raoof AA, Chiu P, Ramtoola Z, Cumming IK, Teng C, Weinbach SP, et al. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci. 2004;93(6):1431\u20139. https:\/\/doi.org\/10.1002\/jps.20051.","journal-title":"J Pharm Sci"},{"issue":"593","key":"562_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe9117","volume":"13","author":"P Gennemark","year":"2021","unstructured":"Gennemark P, Walter K, Clemmensen N, Reki\u0107 D, Nilsson CAM, Kn\u00f6chel J, et al. An oral antisense oligonucleotide for PCSK9 inhibition. Sci Transl Med. 2021;13(593): eabe9117. https:\/\/doi.org\/10.1126\/scitranslmed.abe9117.","journal-title":"Sci Transl Med."},{"issue":"22","key":"562_CR65","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acs.jmedchem.1c01599","volume":"64","author":"TJ Tucker","year":"2021","unstructured":"Tucker TJ, Embrey MW, Alleyne C, Amin RP, Bass A, Bhatt B, et al. A series of novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitors. J Med Chem. 2021;64(22):16770\u2013800. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01599.","journal-title":"J Med Chem"},{"issue":"5483","key":"562_CR66","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.289.5483.1352","volume":"289","author":"L Steidler","year":"2000","unstructured":"Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289(5483):1352\u20135. https:\/\/doi.org\/10.1126\/science.289.5483.1352.","journal-title":"Science"},{"issue":"6","key":"562_CR67","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.cgh.2006.03.028","volume":"4","author":"H Braat","year":"2006","unstructured":"Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2006;4(6):754\u20139. https:\/\/doi.org\/10.1016\/j.cgh.2006.03.028.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"562_CR68","doi-asserted-by":"publisher","first-page":"11322","DOI":"10.3390\/ijms222111322","volume":"22","author":"JW Kim","year":"2021","unstructured":"Kim JW, Kim SY. The era of Janus Kinase inhibitors for inflammatory bowel disease treatment. Int J Mol Sci. 2021;22(21):11322. https:\/\/doi.org\/10.3390\/ijms222111322.","journal-title":"Int J Mol Sci"},{"key":"562_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106958","volume":"5","author":"BG Feagan","year":"2022","unstructured":"Feagan BG, Schreiber S, Afzali A, Rieder F, Hyams J, Kollengode K, et al. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn\u2019s disease: the YELLOWSTONE clinical trial program. Contemp Clin Trials. 2022;5: 106958. https:\/\/doi.org\/10.1016\/j.cct.2022.106958.","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"562_CR70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/MEG.0000000000001730","volume":"32","author":"LA Lucaciu","year":"2020","unstructured":"Lucaciu LA, Seicean R, Seicean A. Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why?\u2014a systematic review. Eur J Gastroenterol Hepatol. 2020;32(6):669\u201377. https:\/\/doi.org\/10.1097\/MEG.0000000000001730.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00562-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T22:43:20Z","timestamp":1668120200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00562-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00562-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"13 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DB devised and wrote the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This publication was supported in part by a grant from Science Foundation Ireland (SFI) under Grant number 13\/RC\/2073_2 and with support from the European Regional Development Fund.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DB has a current research collaboration and consultancy with Janssen. As the company was mentioned in the article in relation to their collaboration with Protagonist Ltd, this could be interpreted as a perceived conflict of interest, hence its full disclosure. Similarly, BMS was also cited, and it will be funding a postdoctoral fellowship in his lab from 2023. DB declares that he consults for Biotech and Pharma companies working on oral administration of peptides, proteins and antibodies for systemic delivery.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data cited in this review was from peer-reviewed literature, company websites, and was also sourced from Springer\u2019s AdisInsight database. Source data availability can be requested from the cited authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}